Serum metabolomics reveals irreversible inhibition of fatty acid beta-oxidation through the suppression of PPARalpha activation as a contributing mechanism of acetaminophen-induced hepatotoxicity.
about
The Need for Biomarkers in Diagnosis and Prognosis of Drug-Induced Liver Disease: Does Metabolomics Have Any Role?Circulating mitochondrial biomarkers for drug-induced liver injuryLC-MS-based metabolomicsTransgenic mice and metabolomics for study of hepatic xenobiotic metabolism and toxicityIdentification of modulators of the nuclear receptor peroxisome proliferator-activated receptor α (PPARα) in a mouse liver gene expression compendiumComparison of Bile Acids and Acetaminophen Protein Adducts in Children and Adolescents with Acetaminophen ToxicityThe metabolomic window into hepatobiliary disease.Targeted liquid chromatography-mass spectrometry analysis of serum acylcarnitines in acetaminophen toxicity in children.Serum mitochondrial biomarkers and damage-associated molecular patterns are higher in acetaminophen overdose patients with poor outcome.Identification of a metabolic biomarker panel in rats for prediction of acute and idiosyncratic hepatotoxicity.Proteomic analysis of acetaminophen-induced changes in mitochondrial protein expression using spectral countingSaikosaponin d protects against acetaminophen-induced hepatotoxicity by inhibiting NF-κB and STAT3 signalingIncreased excretion of c4-carnitine species after a therapeutic acetylsalicylic Acid dose: evidence for an inhibitory effect on short-chain Fatty Acid metabolismDietary saturated and monounsaturated fats protect against acute acetaminophen hepatotoxicity by altering fatty acid composition of liver microsomal membrane in ratsAcetaminophen: Dose-Dependent Drug Hepatotoxicity and Acute Liver Failure in Patients.The ubiquitin ligase MuRF1 regulates PPARα activity in the heart by enhancing nuclear export via monoubiquitination.Translational biomarkers of acetaminophen-induced acute liver injuryPeroxisome proliferator-activated receptor alpha induction of uncoupling protein 2 protects against acetaminophen-induced liver toxicity.Identification of Identical Transcript Changes in Liver and Whole Blood during Acetaminophen Toxicity.Lipidomic profiling reveals protective function of fatty acid oxidation in cocaine-induced hepatotoxicity.Metabolomics reveals an essential role for peroxisome proliferator-activated receptor α in bile acid homeostasis.Targeted Metabolomics of Serum Acylcarnitines Evaluates Hepatoprotective Effect of Wuzhi Tablet (Schisandra sphenanthera Extract) against Acute Acetaminophen Toxicity.Stable isotope- and mass spectrometry-based metabolomics as tools in drug metabolism: a study expanding tempol pharmacology.Loss of 5-lipoxygenase activity protects mice against paracetamol-induced liver toxicityIncreased nitroxidative stress promotes mitochondrial dysfunction in alcoholic and nonalcoholic fatty liver disease.Robust protein nitration contributes to acetaminophen-induced mitochondrial dysfunction and acute liver injuryMetabolomics: an essential tool to understand the function of peroxisome proliferator-activated receptor alpha.Metabolomics reveals that tumor xenografts induce liver dysfunction.Low Dose Acetaminophen Induces Reversible Mitochondrial Dysfunction Associated with Transient c-Jun N-Terminal Kinase Activation in Mouse Liver.Rifampicin-activated human pregnane X receptor and CYP3A4 induction enhance acetaminophen-induced toxicityComparative metabonomic analysis of hepatotoxicity induced by acetaminophen and its less toxic meta-isomer.Role of cytochrome P450 2E1 in protein nitration and ubiquitin-mediated degradation during acetaminophen toxicity.Radiation metabolomics. 3. Biomarker discovery in the urine of gamma-irradiated rats using a simplified metabolomics protocol of gas chromatography-mass spectrometry combined with random forests machine learning algorithm.Acylcarnitine profiles in acetaminophen toxicity in the mouse: comparison to toxicity, metabolism and hepatocyte regeneration.Circulating acylcarnitines as biomarkers of mitochondrial dysfunction after acetaminophen overdose in mice and humansMetabolic bioactivation and drug-related adverse effects: current status and future directions from a pharmaceutical research perspective.The future of toxicity testing.Current trends and challenges in sample preparation for global metabolomics using liquid chromatography-mass spectrometry.Mechanistic biomarkers in acetaminophen-induced hepatotoxicity and acute liver failure: from preclinical models to patients.Metabolic phenotyping applied to pre-clinical and clinical studies of acetaminophen metabolism and hepatotoxicity.
P2860
Q26772999-898D135B-15C3-4095-8716-BB675CA9C282Q26778353-C0A2FEBC-9FD2-47CF-BCD5-CE115E7E0DC0Q27015012-67AAA925-8621-40AC-B3FF-42D04293F62BQ28087473-C16B894C-CBDC-4A8B-9C0E-21EF8494FE5FQ28543435-85F0A604-84CB-4AC1-B1C3-65A0B83608D5Q28546783-3DF264D0-C3C2-4394-8654-1DD27E407D67Q33893457-EE36B380-852D-4E69-B2A0-3B0B5E174FEEQ34015035-FE0BE84D-46DE-4A08-A9A5-596814A66767Q34241967-4F860834-38C9-4B07-A561-060FFC3B1371Q34376979-6417A872-56BE-43FA-9293-A59B1C056831Q34819836-611193EE-CCDE-4566-B86F-043FC1D24C6EQ35224589-FEB41EB7-6DBE-428C-97FB-2C76872AC213Q35428738-8206B7D0-08E7-4DFD-B89F-FE7940F36A1CQ35546185-067E0CDC-AD50-4106-9432-983A8C7702A5Q35903687-FE565376-7BD8-4BA3-B55B-48FB68DA1111Q35911960-9F668639-90AC-496A-9C86-EA96DC2B5650Q36001451-1C087984-B78F-485B-B46C-C6956CDE50EFQ36044209-83A3ED5F-AD2A-44C2-BC1F-8FC29B46F7F0Q36206111-E6F25978-3897-4248-A761-96E3EDBFB7FAQ36302732-8D44EBFC-7A65-4643-BC29-421D2F81649EQ36520380-F249717C-7E69-4EEA-931A-396B1EBEFE00Q36619354-128C3736-4687-4F08-A3CF-AB06F94BC0BFQ36676188-EB151F4B-2656-4E00-9096-6565AF5CACD8Q36744182-10B0BB14-31B2-4736-891F-5A45A49D14A4Q36831136-8B836131-EB7D-41E2-B95C-E93EDAF69C9FQ36923111-C86781E5-F09C-4B61-9C86-2F417D0C7B57Q36949274-2244BB20-2742-4005-B72C-D88A80E00ABCQ37072851-46E457AD-3E26-4B53-BE9B-629ED64EDFABQ37228591-BA9F2FE9-EE8C-415A-B376-1D7339977010Q37266276-FB3C3BCD-D72A-476A-870C-74279821FA10Q37408083-4A2BC673-CD53-4629-81DF-85B689EC2471Q37442120-BF348BE5-1A70-4167-9D4E-5CD4C104E78AQ37468612-AFF64875-57FB-4209-97B4-1582C364C738Q37512777-2D363540-1A94-4CF0-B169-FD9E601D9111Q37624894-B0464C53-CDD7-48F7-9ED3-89F470212314Q37638755-D30283EF-B6C0-46A2-8A8E-93B56D834EC6Q37767386-0F4DABC2-F9F6-4D0F-9D38-FAC5D89153EFQ38009236-0F384654-7A6E-4761-8E31-7CE8BE62C735Q38212434-A214C19F-007C-4637-AE30-4CA8E71E2B6FQ38297772-E84AFECB-5FFA-47BC-87CA-C6EA3286FDC2
P2860
Serum metabolomics reveals irreversible inhibition of fatty acid beta-oxidation through the suppression of PPARalpha activation as a contributing mechanism of acetaminophen-induced hepatotoxicity.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Serum metabolomics reveals irr ...... nophen-induced hepatotoxicity.
@en
Serum metabolomics reveals irr ...... nophen-induced hepatotoxicity.
@nl
type
label
Serum metabolomics reveals irr ...... nophen-induced hepatotoxicity.
@en
Serum metabolomics reveals irr ...... nophen-induced hepatotoxicity.
@nl
prefLabel
Serum metabolomics reveals irr ...... nophen-induced hepatotoxicity.
@en
Serum metabolomics reveals irr ...... nophen-induced hepatotoxicity.
@nl
P2093
P2860
P356
P1476
Serum metabolomics reveals irr ...... nophen-induced hepatotoxicity.
@en
P2093
Frank J Gonzalez
Jeffrey R Idle
Kristopher W Krausz
Yatrik M Shah
P2860
P304
P356
10.1021/TX800464Q
P577
2009-04-01T00:00:00Z